AI Stocks Lose Steam as Capital Rotates — Eli Lilly, AbbVie Near Record Highs
AI stocks faced volatility, prompting capital rotation into pharmaceuticals. Eli Lilly (LLY) and AbbVie (ABBV) neared record highs, with LLY at $1,251.61 and ABBV at $283.40. Healthcare ETF XLV hit $177.19. LLY's gains were driven by its GLP-1 dominance and M&A activity, while ABBV's rally followed positive Skyrizi data. Other large-cap pharma stocks also rose, but biotech ETF XBI declined 2.8% over a month.
How this was made
The 30-second read
Why it matters
The shift lifts pharma equities and related ETFs, while AI stocks face pressure; the move is driven by risk‑aversion rather than new corporate events.
Market read
Defensive capital flow boosts health‑care stocks and ETFs, potentially dampening AI‑sector momentum.
What to watch
Upcoming interest‑rate outlook and potential AI‑related policy changes could alter the rotation.
Background
The article discusses a sector‑wide rotation from high‑growth AI equities to defensive large‑cap pharmaceutical names amid volatility in AI stocks.
Ticker impact
Eli Lilly shares rose 3.6% to a record‑close as capital rotated into large‑cap pharma amid AI stock volatility.
upward pressure as investors seek stable earnings exposure
The article links the price gain directly to a sector‑wide shift, not to a new corporate event.
AbbVie shares edged up 0.56% to a near‑record high after new subcutaneous Skyrizi data and patent extension expectations.
moderate upside as the formulation data supports future sales
The article reports fresh clinical data, but the move is modest and part of a broader sector rally.
Gilead Sciences advanced 7.7% over five sessions despite no specific catalyst, driven by the same defensive rotation.
upward pressure from sector rotation
Price move is attributed to macro flow rather than a company‑specific event.
Amgen gained 7.0% over five sessions, similarly without a direct news catalyst.
upward pressure from defensive allocation
Movement is a spillover from the sector rotation narrative.
Merck & Co. rose 2.3% as part of the broader healthcare rally.
slight upside
No specific catalyst; gain mirrors sector momentum.
UnitedHealth Group jumped 9.1% after reporting solid Q3 earnings, reinforcing confidence in the health sector.
upward pressure from earnings beat and defensive bias
Earnings beat is a concrete corporate event driving the move.
SPDR Health Care Select Sector ETF hit a record high of $177.19, reflecting the inflow into large‑cap pharma.
upward pressure from sector allocation
ETF performance directly mirrors the sector rotation described.
Market effects
Healthcare sector gains as investors rotate from AI to stable pharma stocks.
U.S. equity markets see a defensive shift toward large‑cap health care.
Moderate, as the rotation influences global risk‑on/off dynamics.
Counterpoint
If AI sentiment rebounds, the defensive flow could reverse, pressuring pharma stocks.
Key entities
- companyEli Lilly
Large‑cap pharma benefiting from defensive rotation.
- companyAbbVie
Pharma with new Skyrizi formulation data.
- companyUnitedHealth Group
Health insurer that beat Q3 earnings.
